Home/Filings/4/0001133416-25-000054
4//SEC Filing

Jamil Khurram 4

Accession 0001133416-25-000054

CIK 0001133416other

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 4:02 PM ET

Size

20.6 KB

Accession

0001133416-25-000054

Insider Transaction Report

Form 4
Period: 2025-11-13
Jamil Khurram
Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2025-11-13$5.47/sh21,867$119,6124,479 total
  • Exercise/Conversion

    Stock option (right to buy)

    2025-11-1316,25048,750 total
    Exercise: $1.23From: 2025-06-30Exp: 2035-01-23Common stock (16,250 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-13$2.20/sh+41,500$91,30045,979 total
  • Sale

    Common Stock

    2025-11-13$5.47/sh41,500$227,0054,479 total
  • Exercise/Conversion

    Common Stock

    2025-11-13$2.50/sh+41,500$103,75045,979 total
  • Sale

    Common Stock

    2025-11-13$5.47/sh41,500$227,0054,479 total
  • Exercise/Conversion

    Common stock

    2025-11-13$1.23/sh+16,250$19,98820,729 total
  • Sale

    Common stock

    2025-11-13$5.47/sh16,250$88,8884,479 total
  • Exercise/Conversion

    Stock option (right to buy)

    2025-11-1341,500108,500 total
    Exercise: $2.20From: 2025-03-31Exp: 2034-03-20Common Stock (41,500 underlying)
  • Exercise/Conversion

    Stock option (right to buy)

    2025-11-1341,50058,500 total
    Exercise: $2.50From: 2025-07-31Exp: 2034-08-01Common Stock (41,500 underlying)
Footnotes (5)
  • [F1]The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
  • [F2]The shares were sold in multiple transactions at prices ranging from $5.41 to $5.89. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  • [F3]The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027.
  • [F4]The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025.
  • [F5]The options vest as follows: 16,250 on each of June 30, 2025, December 31, 2025, June 30, 2026, and December 31, 2026.

Issuer

GALECTIN THERAPEUTICS INC

CIK 0001133416

Entity typeother

Related Parties

1
  • filerCIK 0002032345

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 4:02 PM ET
Size
20.6 KB